| Mrs Alison Lindsey North, CNM | |
|
4245 Roosevelt Way Ne, Seattle, WA 98105-6008 | |
| (206) 598-5500 | |
| Not Available |
| Full Name | Mrs Alison Lindsey North |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 22 Years |
| Location | 4245 Roosevelt Way Ne, Seattle, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205915790 | NPI | - | NPPES |
| 1205915790 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | AP30006324 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Washington Medical Ctr | Seattle, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Association Of University Physicians | 0446162697 | 3009 |
News Archive
MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway. The antibody, AMG 108, a fully human monoclonal antibody to the IL-1 receptor, has been studied in multiple phase 1 and phase 2 clinical trials and will now be explored by MedImmune for its potential against certain inflammatory diseases.
For years, parents of children with high blood lead concentrations have been advised by health experts to provide their kids foods rich in iron, calcium and vitamin C.
Researchers from the Institute of Biomedicine of Seville (IBIS) have presented a study carried out in the Clinical Biochemistry Service of the Virgen del Rocío University Hospital which identifies the values for six biochemical biomarkers that indicate a patient may be infected with SARS-COV-2 (COVID-19).
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.
The brains of Alzheimer patients have high accumulations of the material beta-amyloid, which appear in the form of plaques. The precursors of these plaques are believed to be the underlying cause of the nerve cell loss that leads to the disruptions in memory that characterize Alzheimer's disease. The main aim of many Alzheimer therapies is therefore to inhibit the formation of beta-amyloid. Since beta-amyloid is cleaved from the so-called amyloid precursor protein (APP), scientists have focused on stopping the two enzymes that attack the precursor protein. These act like molecular scissors and cut out the beta-amyloid fragment. Blocking these scissors precludes the formation of beta-amyloid.
› Verified 5 days ago
| Entity Name | The Association Of University Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244 |
News Archive
MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway. The antibody, AMG 108, a fully human monoclonal antibody to the IL-1 receptor, has been studied in multiple phase 1 and phase 2 clinical trials and will now be explored by MedImmune for its potential against certain inflammatory diseases.
For years, parents of children with high blood lead concentrations have been advised by health experts to provide their kids foods rich in iron, calcium and vitamin C.
Researchers from the Institute of Biomedicine of Seville (IBIS) have presented a study carried out in the Clinical Biochemistry Service of the Virgen del Rocío University Hospital which identifies the values for six biochemical biomarkers that indicate a patient may be infected with SARS-COV-2 (COVID-19).
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.
The brains of Alzheimer patients have high accumulations of the material beta-amyloid, which appear in the form of plaques. The precursors of these plaques are believed to be the underlying cause of the nerve cell loss that leads to the disruptions in memory that characterize Alzheimer's disease. The main aim of many Alzheimer therapies is therefore to inhibit the formation of beta-amyloid. Since beta-amyloid is cleaved from the so-called amyloid precursor protein (APP), scientists have focused on stopping the two enzymes that attack the precursor protein. These act like molecular scissors and cut out the beta-amyloid fragment. Blocking these scissors precludes the formation of beta-amyloid.
› Verified 5 days ago
| Entity Name | University Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326002049 PECOS PAC ID: 3274445150 Enrollment ID: O20040105000544 |
News Archive
MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway. The antibody, AMG 108, a fully human monoclonal antibody to the IL-1 receptor, has been studied in multiple phase 1 and phase 2 clinical trials and will now be explored by MedImmune for its potential against certain inflammatory diseases.
For years, parents of children with high blood lead concentrations have been advised by health experts to provide their kids foods rich in iron, calcium and vitamin C.
Researchers from the Institute of Biomedicine of Seville (IBIS) have presented a study carried out in the Clinical Biochemistry Service of the Virgen del Rocío University Hospital which identifies the values for six biochemical biomarkers that indicate a patient may be infected with SARS-COV-2 (COVID-19).
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.
The brains of Alzheimer patients have high accumulations of the material beta-amyloid, which appear in the form of plaques. The precursors of these plaques are believed to be the underlying cause of the nerve cell loss that leads to the disruptions in memory that characterize Alzheimer's disease. The main aim of many Alzheimer therapies is therefore to inhibit the formation of beta-amyloid. Since beta-amyloid is cleaved from the so-called amyloid precursor protein (APP), scientists have focused on stopping the two enzymes that attack the precursor protein. These act like molecular scissors and cut out the beta-amyloid fragment. Blocking these scissors precludes the formation of beta-amyloid.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Alison Lindsey North, CNM Po Box 50095, Seattle, WA 98145-5095 Ph: (206) 543-6420 | Mrs Alison Lindsey North, CNM 4245 Roosevelt Way Ne, Seattle, WA 98105-6008 Ph: (206) 598-5500 |
News Archive
MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway. The antibody, AMG 108, a fully human monoclonal antibody to the IL-1 receptor, has been studied in multiple phase 1 and phase 2 clinical trials and will now be explored by MedImmune for its potential against certain inflammatory diseases.
For years, parents of children with high blood lead concentrations have been advised by health experts to provide their kids foods rich in iron, calcium and vitamin C.
Researchers from the Institute of Biomedicine of Seville (IBIS) have presented a study carried out in the Clinical Biochemistry Service of the Virgen del Rocío University Hospital which identifies the values for six biochemical biomarkers that indicate a patient may be infected with SARS-COV-2 (COVID-19).
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.
The brains of Alzheimer patients have high accumulations of the material beta-amyloid, which appear in the form of plaques. The precursors of these plaques are believed to be the underlying cause of the nerve cell loss that leads to the disruptions in memory that characterize Alzheimer's disease. The main aim of many Alzheimer therapies is therefore to inhibit the formation of beta-amyloid. Since beta-amyloid is cleaved from the so-called amyloid precursor protein (APP), scientists have focused on stopping the two enzymes that attack the precursor protein. These act like molecular scissors and cut out the beta-amyloid fragment. Blocking these scissors precludes the formation of beta-amyloid.
› Verified 5 days ago
Noelle D Brodeur, CNM, ARNP Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1101 Madison St Ste 700, Seattle, WA 98104 Phone: 206-215-6300 Fax: 206-215-6301 | |
Victoria G Speck, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 5350 Tallman Ave Nw Ste 420, Seattle, WA 98107 Phone: 206-781-6161 Fax: 206-781-6285 | |
Aliscia Rose Lindeke, CNM, RN Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 401 Broadway, Suite 2075, Seattle, WA 98104 Phone: 206-744-1600 | |
Deborah Blue, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 10330 Meridian Ave N, Suite 190, Seattle, WA 98133 Phone: 206-368-6670 | |
Megan Kathleen Dunn, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1550 N 115th St, Seattle, WA 98133 Phone: 206-520-5000 | |
Kimberly A Kight Johansen, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1959 Ne Pacific St., Seattle, WA 98195 Phone: 206-520-5000 | |
Mia Elizabeth Pelt, RN, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 5350 Tallman Ave Nw, Suite 420, Seattle, WA 98107 Phone: 206-781-6080 |